On December 23, Yuanda Pharmaceutical announced that it had reached a product cooperation agreement with Yuer Pharmaceutical. Yuanda Pharmaceutical will receive exclusive commercial rights within the cooperative channel in mainland China of Neffy®, the world's first adrenaline nasal spray for emergency treatment of type I allergic reactions, as well as non-exclusive commercial rights in Hong Kong, China. This cooperation covers 2 mg and 1 mg specifications, which are suitable for adults, children over 30 kg, and children between 15 and 30 kg, respectively. In December 2024, Uminsu® submitted a marketing application to the State Drug Administration and was accepted.

On December 23, Yuanda Pharmaceutical announced that it had reached a product cooperation agreement with Yuer Pharmaceutical. Yuanda Pharmaceutical will receive exclusive commercial rights within the cooperative channel in mainland China of Neffy®, the world's first adrenaline nasal spray for emergency treatment of type I allergic reactions, as well as non-exclusive commercial rights in Hong Kong, China. This cooperation covers 2 mg and 1 mg specifications, which are suitable for adults, children over 30 kg, and children between 15 and 30 kg, respectively. In December 2024, Uminsu® submitted a marketing application to the State Drug Administration and was accepted.